Media registration
ESMO welcomes media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card. Media representatives are required to observe and abide by the ESMO Media Policy which applies to all ESMO events.
To register for the event, please fill out the Media Registration Form
Complete the Media Registration Form
Media registration in advance is strongly recommended although on-site registration will still be possible. Further information for press representatives will be made available over the following weeks.
Publication schedule for accepted abstracts
- Abstracts accepted for presentation during ESMO Breast Cancer 2019 (Proffered Paper, Mini Oral and Poster) and for publication in the ESMO Breast Cancer 2019 Abstract Book, will be published online on the ESMO Breast Cancer 2019 website on 1 May 2019, 12:00 Central European Summer Time (CEST).
- Late-breaking abstracts (LBA) accepted for presentation during ESMO Breast Cancer 2019 will be made public at the start of the official Congress session during which they are presented.
Press programme
Following abstracts are included in the Congress Press Programme and will be accompanied by a press release.
Please kindly note that some of the embargoes are different from the ones stated in the table above.
Upon publication, direct link to the press releases will be added.
FPN |
Abstract Title |
First author |
Embargo lift date/time |
Press release |
|---|---|---|---|---|
42P_PR |
Painting the global picture of HER2-testing for breast cancer. The ONCOLLEGE-001 survey study |
S. Altuna |
30 April 2019 at 00:05 (CEST) |
|
101P_PR and 102P_PR |
Breast Cancer in Young Women - a multi-center 10-year experience Breast cancer early recurrences in young women |
I. Eiriz S. Cima |
30 April 2019 at 00:05 (CEST) |
|
158P_PR and 159P_PR |
Intermittent versus continuous chemotherapy beyond first-line for patients with HER2-negative advanced breast cancer (BOOG 2010-02) Influence on quality of life of chemotherapy scheduling for patients with advanced HER2-negative breast cancer |
F. Erdkamp A. Claessens |
30 April 2019 at 00:05 (CEST) |
|
202P_PR |
Adherence to Dietary Guidelines (DG) and Body Weight Change (BWC) in Early-stage Breast Cancer (EBC): a prospective trial in patients submitted to nutrition evidence-based educational intervention |
L. Carbognin |
30 April 2019 at 00:05 (CEST) |
|
150O_PR |
Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC)- The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG) |
J. Huober |
1 May 2019 at 12:00 (CEST) |
Third-party media activities
Media activities initiated by third parties during or in connection with ESMO Breast Cancer 2019, including, but not limited to:
- Meetings such as press conferences, media briefings, educational sessions for media representatives, as well as
- PR activities, such as press releases, news, articles, interviews, etc.
are subject to the ESMO Policy on Third-Party Media Activities. This policy aims to guarantee proper and correct distribution of oncology and cancer-related information to media representatives in connection with the conference. Press events in or outside the congress centre but concomitant with/or during breaks of the scientific programme of ESMO Breast Cancer 2019 are subject to ESMO Press Office approval. Please submit your first request through the following form.
Blackout times
During Blackout times any media activity initiated by third parties is not allowed.
Day |
Time |
2 May 2019 |
13:30 – 18:00 |
3 May 2019 |
07:45 – 18:15 |
4 May 2019 |
07:45 – 12:15 |
Contact
ESMO Press Office
E-mail: media@esmo.org
Mashup Communications GmbH
Contact: Stefanie Möser
Mashup Communications GmbH has been appointed the official ESMO partner for German speaking journalists in connection with the ESMO Breast Cancer Congress 2019
E-mail: Mashup Communications